Growth Metrics

Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (1y) (2011 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCF Growth (1y) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 198.34%
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 467.41%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -14,223.53%
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 453.08%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -125.22%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 53.46%
10 Ligand Pharmaceuticals 4.61 Bn 3.83 Bn 48.45 Mn -136.34%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -136.34%
Dec 31, 2025 253.08%
Sep 30, 2025 53.63%
Jun 30, 2025 162.99%
Mar 31, 2025 -193.22%
Dec 31, 2024 230.62%
Sep 30, 2024 625.25%
Jun 30, 2024 46.99%
Mar 31, 2024 -37.93%
Dec 31, 2023 -92.43%
Sep 30, 2023 -637.71%
Jun 30, 2023 -520.64%
Mar 31, 2023 1,065.38%
Dec 31, 2022 1,146.58%
Sep 30, 2022 -181.80%
Jun 30, 2022 4.68%
Mar 31, 2022 71.27%
Dec 31, 2021 99.05%
Sep 30, 2021 -99.58%
Jun 30, 2021 -328.15%
Mar 31, 2021 -134.16%
Dec 31, 2020 -165.35%
Sep 30, 2020 810.76%
Jun 30, 2020 -100.87%
Mar 31, 2020 468.02%
Dec 31, 2019 -293.29%
Sep 30, 2019 -719.49%
Jun 30, 2019 173.81%
Mar 31, 2019 -141.25%
Dec 31, 2018 -223.55%
Sep 30, 2018 128.19%
Jun 30, 2018 102.56%
Mar 31, 2018 474.85%
Dec 31, 2017 82.13%
Sep 30, 2017 -208.93%
Jun 30, 2017 64.96%
Mar 31, 2017 87.74%
Dec 31, 2016 -1,954.24%
Sep 30, 2016 274.38%
Jun 30, 2016 152.25%
Mar 31, 2016 -1,288.84%
Dec 31, 2015 117.88%
Sep 30, 2015 -108.71%
Jun 30, 2015 -3,790.06%
Mar 31, 2015 315.77%
Dec 31, 2014 -344.50%
Sep 30, 2014 6,364.22%
Jun 30, 2014 75.96%
Mar 31, 2014 118.22%
Dec 31, 2013 74.88%
Sep 30, 2013 -78.11%
Jun 30, 2013 228.03%
Mar 31, 2013 -368.42%
Dec 31, 2012 -0.10%
Sep 30, 2012 -25.13%
Jun 30, 2012 73.30%
Mar 31, 2012 1.82%
Dec 31, 2011 2,647.87%
Sep 30, 2011 -311.74%